BLTE · Belite Bio, Inc · Webcasts, Transcripts & Audio
$127.38
-23.64 (-15.65%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$5.17B
Shares
40.61M
Volume · Nov 20
1.04M
Avg daily vol (3M)
194.38K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Belite Bio, Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Belite Bio, Inc (BLTE), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-12
Belite Bio, Inc (BLTE) Q3 2026 Earnings Call Transcript
Positive tone
International regulatory expansion
U.S. regulatory review
Losses and increased operating expenses
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-08-13
Belite Bio, Inc (BLTE) Q2 2026 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-20
Belite Bio, Inc (BLTE) Q1 2026 Earnings Call Transcript
Confident tone
NDA submission and FDA approval timeline
Financial position and operating expenses
Dragon 2 / Japan registration trial
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-02
Belite Bio, Inc (BLTE) Q4 2025 Earnings Call Transcript
Confident tone
NDA submission and regulatory pathway
International/ex-US regulatory strategy and partnering
Prevalence and pediatric expansion
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q2
2025-08-11
Belite Bio, Inc (BLTE) Q2 2025 Earnings Call Transcript
Confident tone
Tinlarebant clinical progress
Geographic atrophy (PHOENIX) trial
Commercialization planning
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Date not confirmed
Belite Bio, Inc (BLTE) Q1 2025 Earnings Call Transcript
Confident tone
Phase 3 DRAGON (Stargardt) interim results
Tinlarebant drug profile and safety
PHOENIX Phase 3 trial in geographic atrophy
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Date not confirmed
Belite Bio, Inc (BLTE) Q4 2024 Earnings Call Transcript
Confident tone
Phase 3 DRAGON trial in Stargardt disease
Enrollment dropout rates
Phase 3 PHOENIX trial in GA
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-19
Belite Bio, Inc (BLTE) Q3 2024 Earnings Call Transcript
Confident tone
Tinlarebant clinical pipeline progress
Phase 2 Stargardt efficacy results
Geographic atrophy positioning vs complement inhibitors
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Date not confirmed
Belite Bio, Inc (BLTE) Q2 2024 Earnings Call Transcript
Confident tone
Tinlarebant clinical programs
Japan regulatory strategy
Phase II Stargardt data
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Date not confirmed
Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript
Confident tone
Stargardt disease Phase 2 data
Stargardt Phase 3 (DRAGON) progress
Geographic Atrophy (GA) Phase 3
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Date not confirmed
Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Date not confirmed
Belite Bio, Inc (BLTE) Q3 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Date not confirmed
Belite Bio, Inc (BLTE) Q2 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Date not confirmed
Belite Bio, Inc (BLTE) Q1 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Date not confirmed
Belite Bio, Inc (BLTE) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q2
2022-06-30
Date not confirmed
Belite Bio, Inc (BLTE) Q2 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–16 of 16 webcasts
Key facts
CIK
1889109
CUSIP
07782B104
13F (30d)
94 filings
93 filers
Visit website
Investor relations